Pharmaceutical company Bristol-Myers Squibb this week applied for Food and Drug Administration approval of its experimental second-generation protease inhibitor Zrivada (atazanavir). The FDA application included data from Phase III clinical trials showing that the once-a-day drug is as effective as other protease inhibitors and does not cause blood lipid levels to rise, a problem common with existing protease drugs. More than 2,400 people have participated in studies of Zrivada, which is currently available through an early-access program for patients who have failed other anti-HIV medications. A decision by the FDA is expected by early summer.
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to betold.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved














